Novavax COVID-19 vaccine (2023-2024 formula XBB containing) + Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)
ApprovedCompleted 0 watching 0 views this week🔥 Hot
80
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
COVID-19
Conditions
COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection, Upper Respiratory Tract Infection, Upper Respiratory Disease
Trial Timeline
Nov 22, 2023 → Sep 9, 2024
NCT ID
NCT06065176About Novavax COVID-19 vaccine (2023-2024 formula XBB containing) + Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)
Novavax COVID-19 vaccine (2023-2024 formula XBB containing) + Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing) is a approved stage product being developed by Novavax for COVID-19. The current trial status is completed. This product is registered under clinical trial identifier NCT06065176. Target conditions include COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection.
Hype Score Breakdown
Clinical
30
Activity
20
Company
5
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06065176 | Approved | Completed |
Competing Products
20 competing products in COVID-19
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Human COVID-19 immunoglobulin (pH4) for intravenous injection + Placebo | Sinopharm | Phase 2 | 51 |
| Mavrilimumab + Placebos | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| Gimsilumab + Placebo | Roivant Sciences | Phase 2 | 49 |
| Icosapent ethyl | Amarin Corporation | Phase 2 | 44 |
| Bamlanivimab + Placebo + Etesevimab | Eli Lilly | Phase 3 | 77 |
| Infliximab | Celltrion | Phase 2 | 52 |
| CT-P63 and CT-P66 / Placebo | Celltrion | Phase 3 | 77 |
| Enzalutamide Pill | Astellas Pharma | Phase 2 | 52 |
| S-892216 + Placebo | Shionogi | Phase 2 | 52 |
| S-892216 + Carbamazepine | Shionogi | Phase 1 | 33 |
| FOY-305 + Placebo | Ono Pharmaceutical | Phase 3 | 77 |
| Desidustat | Zydus Lifesciences | Phase 2 | 52 |
| LY3819253 + Placebo | Eli Lilly | Phase 1 | 33 |
| Bamlanivimab + Etesevimab + Placebo + VIR-7831 + Bebtelovimab | Eli Lilly | Phase 2 | 52 |
| Bamlanivimab | Eli Lilly | Phase 2 | 52 |
| LY3127804 + Placebo | Eli Lilly | Phase 2 | 52 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 77 |
| Bamlanivimab | Eli Lilly | Pre-clinical | 23 |
| LY3819253 + Placebo + Remdesivir | Eli Lilly | Phase 3 | 77 |
| LY3819253 + LY3832479 + LY3853113 + Placebo | Eli Lilly | Phase 2/3 | 65 |
Other Products from Novavax
protein subunit: Novavax COVID-19 vaccine + Pfizer mRNA COVID-19 vaccineApproved
80
NVX-CoV2705 + PlaceboApproved
80
NVX-CoV2373 + BBIBP-CorV vaccinePhase 3
72
SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period) + SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period) + SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination) + SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)Phase 3
72
RSV-F Vaccine + Phosphate Buffer PlaceboPhase 3
72